This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $483,480 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of red blood cell bisphosphoglycerate mutase (BPGM) deficiency in contributing to cognitive impairment following ischemic stroke.
The research aims to investigate how BPGM deficiency in red blood cells may impact neurovascular function and lead to cognitive impairment in stroke patients. It will utilize a BPGM knockout mouse model to explore this mechanism and potential therapeutic strategies targeting the interaction between red blood cells and the brain vascular system (Aim 1). The project will also assess the clinical relevance of RBC BPGM-related metabolism by examining its association with post-stroke cognitive outcomes in a larger patient cohort (Aim 2). The findings are expected to elucidate the overlooked connection between red blood cells and vascular dysfunction in the development of cognitive impairment and dementia after stroke, laying the groundwork for innovative interventions.
Generated 3/4/25, 7:34 AM